New cancer drug enters first human trials for patients out of options
NCT ID NCT06487624
Summary
This is a first-in-human study to test the safety and find the right dose of a new drug called HCB301. It is for adults with advanced solid tumors or Hodgkin lymphoma that have not responded to standard treatments. The main goals are to see what side effects occur and how the body processes the drug, while also checking for any early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Prisma Health-Upstate
RECRUITINGGreenville, South Carolina, 29605, United States
-
Southern Medical University Zhujiang Hospital
RECRUITINGZhujiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xuzhou Central Hospital
RECRUITINGXuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yantai Yuhuangding Hospital
RECRUITINGYantai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Provincial Cancer Hospital
RECRUITINGHangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.